A single phase II cohort investigated the prognostic role of eosinophils in 41 patients with advanced melanoma treated with a combination therapy of BEMPEG (a PEGylated interleukin-2 [IL-2] prodrug) and nivolumab (22). The gene discussed is IL2; the disease is melanoma.